Omid Hamid, MD, chief of Translational Research and Immunotherapy at The Angeles Clinic, talks about patient responses with single-agent immunotherapy and combination therapies in melanoma.

Hamid explains that the response rate for single-agent immunotherapy treatment is approximately 40%, and for combination treatments, it is approximately 57%. However, these data do not give much information about the long-term benefits of these therapies. Hopefully, comparisons of the overall survival with combination treatments and with single-agent treatment will be forthcoming.

Videos

Omid Hamid, MD, compares the responses of patients with melanoma on single-agent immunotherapy treatment to those on combination therapy treatments.

Omid Hamid on Responses to Single Agent Immunotherapies Compared to Combination

Omid Hamid, MD, chief of Translational Research and Immunotherapy of The Angeles Clinic, discusses some toxicities that come from combination immunotherapies, such as type 1 diabetes and hypoadrenalism.

Despite the ease with which these adverse events can usually be remedied, Hamid urges clinicians to carefully consider a patient’s complaints. If these toxicities are caught early enough, they are less complicated to deal with.

Dr. Omid Hamid discusses some toxicities that come from combination immunotherapies

Omid Hamid, MD

Articles

Omid Hamid on Responses to Single Agent Immunotherapies Compared to Combination

Omid Hamid on Vigilance with Toxicities from Combination Immunotherapies